Suven Life Sciences Ltd.
Fundamentals
- Market cap
- ₹7,024 cr
- ROE
- 0.00%
- Debt / equity
- 0.00
- 52-week range
- 124.35 — 303.00
Company snapshot
Suven Life Sciences Ltd.
Pharmaceuticals
₹10,154 cr
Latest quarter · Mar 2026
Sales₹2 cr
Net profit−₹46 cr
Op. margin−3331.1%
EPS−₹1.73
Strength & growth
Debt / equity0.00×
Current ratio3.21×
Sales CAGR−34.6%
The timeline — 5 notes on Suven Life Sciences Ltd.
June 2026
- 17 Jun 26 · 12:36 PM IST Lead Lead · Earnings · Mid cap
Suven's Ropanicant clears Phase 2b, cuts depression scores 3.6 points vs placebo
The 214-patient trial met its primary endpoint with statistical significance. Suven now pushes to global Phase 3 registrational studies.
- 16 Jun 26 · 9:27 AM IST Brief Brief · Earnings · Mid cap
Suven's experimental cognitive drug clears Phase 1 safety hurdle
SUVN-I6107, Suven's fifth internally discovered neuroscience NCE, showed no serious adverse events in 64 healthy volunteers and is moving into Phase 2.
- 12 Jun 26 · 11:25 AM IST Brief Brief · Mid cap
Suven to show Samelisant Phase 2 data at SLEEP-2026
Three posters on narcolepsy drug cover positive efficacy in daytime sleepiness, cataplexy study design, and Phase 3 plan. Conference runs June 14-17 in Baltimore.
- 04 Jun 26 · 10:56 AM IST Lead Lead · Mid cap
Suven's Alzheimer's drug passes a critical Phase 3 safety check.
An independent board reviewed halfway data and told Suven to press on without changing the trial design or size. Enrollment is now at 88%.